Heart failure drug vericiguat faces new test in tricuspid regurgitation patients
NCT ID NCT07668739
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug vericiguat can improve right heart function and reduce tricuspid regurgitation in 100 adults with heart failure and reduced pumping ability. Participants take vericiguat daily for 9 months, with regular heart scans and walking tests to measure effects. The goal is to see if it lowers hospitalizations and improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vericiguat
What this could lead to
If it works, this could provide a new treatment option for heart failure patients with severe tricuspid regurgitation, potentially reducing hospitalizations and improving quality of life.
What could go wrong
This is a relatively small phase 4 trial (100 participants) testing a drug already approved for heart failure, so the added benefit for this specific condition may be modest or not confirmed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Daejeon St.Mary's Hospital
Daejeon, 34943, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••